The Cluster for Nucleic Acid Therapeutics Munich (C-NATM), an innovation network made up of research institutions and private enterprise, will receive five million euros in funding annually from the German government, the Free State of Bavaria and in part from participating companies starting from 2023. On the condition that it passes an interim evaluation, the project will run for nine years. The spokespersons for the alliance are Professor Thomas Carell, Director of the Institute of Chemical Epigenetics at LMU, a renowned RNA chemist, and Professor Stefan Engelhardt, Director of the Institute of Pharmacology and Toxicology at the Technical University of Munich (TUM), who is specialized in RNA-based therapies. In addition to staff from various disciplines at LMU and TUM, researchers from other research institutions and experts from pharmaceutical companies and start-ups from the region are also taking part in the initiative.
www.clusters4future.de/die-zukunftscluster/die-zukunftscluster-der-zweiten-wettbewerbsrunde/cnatm